| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Robert Yarchoan | |
| Thomas S Uldrick | |||
| Priscila H Gonçalves | |||
| P2860 | cites work | Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A | Q24607716 |
| Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors | Q28190673 | ||
| Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma | Q28242984 | ||
| Kaposi's sarcoma in homosexual men-a report of eight cases | Q28260393 | ||
| Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California | Q28273721 | ||
| KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma | Q28284765 | ||
| Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection | Q28299060 | ||
| Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas | Q28299069 | ||
| Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China | Q28750969 | ||
| Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease | Q29619158 | ||
| Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T-cell phenotype | Q30656272 | ||
| HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study | Q31042536 | ||
| High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease | Q33183484 | ||
| Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma | Q33187555 | ||
| Pathology of rituximab-induced Kaposi sarcoma flare | Q33354623 | ||
| Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). | Q33428328 | ||
| A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus | Q33559699 | ||
| Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir | Q39588898 | ||
| Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir | Q39594055 | ||
| Demographic indicators and risk of infection with human herpesvirus type 8 in Central Italy. | Q39786544 | ||
| How I treat HIV-associated multicentric Castleman disease | Q39850035 | ||
| Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells | Q39877852 | ||
| Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells | Q40105402 | ||
| Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas | Q40258774 | ||
| Human herpesvirus 8-related Castleman disease in the absence of HIV infection. | Q40265089 | ||
| The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. | Q40333151 | ||
| Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. | Q40351293 | ||
| iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease | Q40382679 | ||
| High seroprevalence of human herpesvirus 8 and herpes simplex virus 2 infections in men who have sex with men in Shanghai, China | Q40493967 | ||
| Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients | Q40674328 | ||
| HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma | Q40747284 | ||
| Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus | Q40807418 | ||
| Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution | Q40821708 | ||
| Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication | Q40909738 | ||
| Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma | Q40972068 | ||
| Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines | Q41088030 | ||
| Epidemiology of classic Kaposi's sarcoma, with special reference to mediterranean population | Q41109755 | ||
| Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. | Q41189777 | ||
| Activation of NF-kappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype | Q41494543 | ||
| Acquired immunodeficiency syndrome is an opportunistic infection and Kaposi's sarcoma results from secondary immune stimulation | Q41534380 | ||
| Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions | Q42049779 | ||
| Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression | Q42059350 | ||
| Oxidative Stress Induces Reactivation of Kaposi's Sarcoma-Associated Herpesvirus and Death of Primary Effusion Lymphoma Cells | Q42166459 | ||
| Seroprevalence of Kaposi's sarcoma-associated herpesvirus among men who have sex with men in Japan | Q42266673 | ||
| Human herpesvirus 8+ polyclonal IgMλ B-cell lymphocytosis mimicking plasmablastic leukemia/lymphoma in HIV-infected patients | Q42273159 | ||
| Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. | Q42502875 | ||
| Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. | Q42646886 | ||
| Prevalence of sexually transmitted infections and enteric protozoa among homosexual men in western Sicily (south Italy). | Q42989910 | ||
| Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study | Q43469561 | ||
| Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. | Q43571673 | ||
| The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. | Q43927346 | ||
| Infectious human herpesvirus 8 in a healthy North American blood donor | Q44132374 | ||
| Pathology of Kaposi's sarcoma | Q37617269 | ||
| Use of saliva as a lubricant in anal sexual practices among homosexual men. | Q37684395 | ||
| Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. | Q38021339 | ||
| Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming | Q38107726 | ||
| Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis | Q38597909 | ||
| Trends in the incidence of cancer in Kampala, Uganda 1991-2010. | Q38862952 | ||
| Geographic Heterogeneity of Prevalence of the Human Herpesvirus 8 in Sub-Saharan Africa: Clues About Etiology | Q38871413 | ||
| Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda | Q38882800 | ||
| Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy | Q38943741 | ||
| Kaposi sarcoma herpesvirus-associated cancers and related diseases | Q38962850 | ||
| Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. | Q39172502 | ||
| Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins | Q39585165 | ||
| High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations | Q33647633 | ||
| Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study | Q33816582 | ||
| Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects | Q33849065 | ||
| Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy | Q33851168 | ||
| p53 inhibition by the LANA protein of KSHV protects against cell death | Q33885642 | ||
| Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. | Q33920405 | ||
| Mucosal shedding of human herpesvirus 8 in men. | Q33924644 | ||
| Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt" | Q33952679 | ||
| An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease | Q34157797 | ||
| Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. | Q34408877 | ||
| Sexual transmission and the natural history of human herpesvirus 8 infection | Q34462040 | ||
| Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. | Q34470355 | ||
| Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group | Q34508292 | ||
| The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells | Q34512207 | ||
| A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma | Q34535352 | ||
| Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma | Q34544861 | ||
| Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma | Q34545955 | ||
| Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? | Q34546123 | ||
| Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. | Q34548882 | ||
| Sirolimus for Kaposi's sarcoma in renal-transplant recipients | Q34556363 | ||
| Trends in cancer risk among people with AIDS in the United States 1980-2002. | Q34569368 | ||
| Transmission of human herpesvirus 8 by blood transfusion. | Q34569442 | ||
| A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. | Q34574095 | ||
| The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. | Q34609235 | ||
| Increasing incidence of cancers associated with the human immunodeficiency virus epidemic | Q34615381 | ||
| Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy | Q34620787 | ||
| Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice | Q34627126 | ||
| Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease | Q34636851 | ||
| Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma | Q34667171 | ||
| The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome | Q34693731 | ||
| Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen | Q34735858 | ||
| Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma | Q34746239 | ||
| Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. | Q34749386 | ||
| A pilot study of cidofovir in patients with kaposi sarcoma | Q44267020 | ||
| High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. | Q44424254 | ||
| Prevalence and correlates of Kaposi's sarcoma-associated herpesvirus infection in a sample of men who have sex with men in Eastern China | Q44565603 | ||
| Human herpesvirus 8- and Epstein-Barr virus-associated solitary B cell lymphoma with a T cell immunophenotype | Q44844922 | ||
| KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma | Q44987723 | ||
| Imatinib-induced regression of AIDS-related Kaposi's sarcoma | Q45168954 | ||
| Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial | Q45401439 | ||
| Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. | Q45769785 | ||
| The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases | Q45862399 | ||
| Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic | Q46149334 | ||
| Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). | Q46501517 | ||
| Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission | Q47604867 | ||
| Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors | Q47688207 | ||
| Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. | Q51846918 | ||
| Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. | Q51958692 | ||
| Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel. | Q52069008 | ||
| Kaposi's Sarcoma | Q54197804 | ||
| Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. | Q55239921 | ||
| Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease | Q56706396 | ||
| Activity of thalidomide in AIDS-related Kaposi's sarcoma | Q56890995 | ||
| Rituximab therapy for HIV-associated Castleman disease | Q58004108 | ||
| Monoclonal Origin of Multicentric Kaposi's Sarcoma Lesions | Q58366797 | ||
| Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease | Q58415972 | ||
| Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease | Q59621855 | ||
| Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis | Q59647770 | ||
| Kaposi's Sarcoma–Associated Herpesvirus DNA Sequences in Prostate Tissue and Human Semen | Q59647839 | ||
| Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee | Q69531286 | ||
| Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma | Q71693375 | ||
| Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways | Q73456324 | ||
| Clonality in Kaposi's sarcoma | Q73609603 | ||
| AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee | Q73690516 | ||
| AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive | Q73718723 | ||
| Serum viral interleukin-6 in AIDS-related multicentric Castleman disease | Q73768899 | ||
| Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen | Q73923367 | ||
| Molecular and pathologic characterization of an AIDS-related body cavity-based lymphoma, including ultrastructural demonstration of human herpesvirus-8: a case report | Q74428500 | ||
| Primary effusion lymphoma: cytopathologic diagnosis using in situ molecular genetic analysis for human herpesvirus 8 | Q74755010 | ||
| The enigmas of Kaposi's sarcoma | Q77752067 | ||
| Progression of classic Kaposi's sarcoma with rituximab | Q81867638 | ||
| Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma | Q83750628 | ||
| Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease | Q84582739 | ||
| Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? | Q34996973 | ||
| Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily | Q35004900 | ||
| The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro | Q35005190 | ||
| Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia | Q35019982 | ||
| Excess cancers among HIV-infected people in the United States | Q35102629 | ||
| Prevalence and correlates of human herpesvirus 8 infection among Peruvian men who have sex with men. | Q35110728 | ||
| High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy | Q35127955 | ||
| Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma | Q35131811 | ||
| Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors | Q35139228 | ||
| Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda | Q35328464 | ||
| Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa | Q35632074 | ||
| Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection | Q35715660 | ||
| Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome | Q35795414 | ||
| Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. | Q35801267 | ||
| Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. | Q35809792 | ||
| Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study | Q35827892 | ||
| Human herpesvirus 8 seroprevalence, China | Q35845813 | ||
| Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. | Q35916171 | ||
| A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa | Q35989731 | ||
| HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice | Q36018434 | ||
| Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy | Q36058281 | ||
| Fifty years of multicentric Castleman's disease | Q36069611 | ||
| Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome. | Q36153930 | ||
| HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis | Q36167185 | ||
| Evidence for multiclonality in multicentric Kaposi's sarcoma | Q36173459 | ||
| RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. | Q36238539 | ||
| Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. | Q36433852 | ||
| Transmission of human herpesvirus type 8 infection within families in american indigenous populations from the Brazilian Amazon | Q36507059 | ||
| Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy | Q36614066 | ||
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 | ||
| Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells | Q37088335 | ||
| Seroprevalence of Kaposi sarcoma-associated herpesvirus and other serologic markers in the Brazilian Amazon | Q37164729 | ||
| Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease | Q37405468 | ||
| Castleman disease: an update on classification and the spectrum of associated lesions | Q37527694 | ||
| Risk factors for early childhood infection of human herpesvirus-8 in Zambian children: the role of early childhood feeding practices | Q37610944 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1903-1916 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | HIV-associated Kaposi sarcoma and related diseases | |
| P478 | volume | 31 |
| Q98159557 | A Rare Case of the Newly Recognized Kaposi Sarcoma Herpesvirus-Associated Disease |
| Q92158822 | A case of progressive lower leg edema |
| Q89320710 | CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma |
| Q60043899 | Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study |
| Q58778363 | Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma |
| Q90646331 | Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity |
| Q57819530 | Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial |
| Q57116991 | Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy |
| Q56941539 | K15 Protein of Kaposi's Sarcoma Herpesviruses Increases Endothelial Cell Proliferation and Migration through Store-Operated Calcium Entry |
| Q59352876 | KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions |
| Q94012444 | Kaposi sarcoma |
| Q92843405 | Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon |
| Q90744475 | Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands |
| Q60922330 | Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV |
| Q58552859 | Non-Hodgkin lymphoma risk in adults living with HIV across five continents |
| Q53686620 | Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. |
| Q99415498 | Rapid Progression of Kaposi's sarcoma complicated with hemophagocytic syndrome in a severely immunosuppressed patient with HIV-infection: a case report |
| Q90537562 | Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review |
| Q92145063 | Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon |
| Q92221509 | Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir |
| Q54217772 | Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. |
| Q92373604 | Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced Cancer |
| Q47227215 | The "Topological Train Ride" of a viral long non-coding RNA. |
| Q94602942 | The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review |
| Q54237459 | Usefulness of Kaposi sarcoma-associated herpesvirus (KSHV)-DNA viral load in whole blood for the diagnosis and monitoring of KSHV-associated diseases. |
Search more.